Literature DB >> 8824702

Varicella-zoster virus: aspects of pathogenesis and host response to natural infection and varicella vaccine.

A M Arvin1, J F Moffat, R Redman.   

Abstract

Events in the pathogenesis of infection and the host response to VZV are very closely linked. Our experiments demonstrate that CD4- and CD8+ T-lymphocyte populations that are targets of cell-associated VZV viremia also mediate protection against severe infection. Diminished cell-mediated immunity predisposes the host to progressive primary or recurrent VZV disease because infected lymphocytes persist in the circulation and carry the virus to major organs, causing pneumonitis, hepatitis, or other life-threatening complications. The live attenuated varicella vaccine induces cell-mediated immunity and protects against or significantly reduces the morbidity associated with primary VZV infections. The universal administration of varicella vaccine is likely to generate new insights about host-virus interactions, particularly in relation to how VZV immunity is maintained, that will be relevant to the design of vaccines for other human herpesviruses.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8824702     DOI: 10.1016/s0065-3527(08)60074-3

Source DB:  PubMed          Journal:  Adv Virus Res        ISSN: 0065-3527            Impact factor:   9.937


  18 in total

1.  Infection of human T lymphocytes with varicella-zoster virus: an analysis with viral mutants and clinical isolates.

Authors:  W Soong; J C Schultz; A C Patera; M H Sommer; J I Cohen
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

2.  Quantitation of varicella-zoster virus DNA in whole blood, plasma, and serum by PCR and electrochemiluminescence.

Authors:  M D de Jong; J F Weel; T Schuurman; P M Wertheim-van Dillen; R Boom
Journal:  J Clin Microbiol       Date:  2000-07       Impact factor: 5.948

3.  Analysis of T cell responses during active varicella-zoster virus reactivation in human ganglia.

Authors:  Megan Steain; Jeremy P Sutherland; Michael Rodriguez; Anthony L Cunningham; Barry Slobedman; Allison Abendroth
Journal:  J Virol       Date:  2013-12-18       Impact factor: 5.103

Review 4.  Diagnosis, antiviral therapy, and prophylaxis of varicella-zoster virus infections.

Authors:  A Sauerbrei
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-02-12       Impact factor: 3.267

5.  Tropism of varicella-zoster virus for human tonsillar CD4(+) T lymphocytes that express activation, memory, and skin homing markers.

Authors:  Chia-Chi Ku; Jorge A Padilla; Charles Grose; Eugene C Butcher; Ann M Arvin
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

6.  Varicella-zoster virus infection of human dendritic cells and transmission to T cells: implications for virus dissemination in the host.

Authors:  A Abendroth; G Morrow; A L Cunningham; B Slobedman
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

Review 7.  Varicella zoster virus immune evasion strategies.

Authors:  Allison Abendroth; Paul R Kinchington; Barry Slobedman
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

Review 8.  Advances in the understanding of the pathogenesis and epidemiology of herpes zoster.

Authors:  Anne A Gershon; Michael D Gershon; Judith Breuer; Myron J Levin; Anne Louise Oaklander; Paul D Griffiths
Journal:  J Clin Virol       Date:  2010-05       Impact factor: 3.168

9.  Impact of varicella-zoster virus on dendritic cell subsets in human skin during natural infection.

Authors:  Jennifer H Huch; Anthony L Cunningham; Ann M Arvin; Najla Nasr; Saskia J A M Santegoets; Eric Slobedman; Barry Slobedman; Allison Abendroth
Journal:  J Virol       Date:  2010-02-03       Impact factor: 5.103

10.  Human sensory neurons derived from induced pluripotent stem cells support varicella-zoster virus infection.

Authors:  Katherine S Lee; Wenbo Zhou; Jonah J Scott-McKean; Kaitlin L Emmerling; Guang-yun Cai; David L Krah; Alberto C Costa; Curt R Freed; Myron J Levin
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.